Premium
Gene–gene interaction between 14‐3‐3 zeta and butyrylcholinesterase modulates Alzheimer′s disease risk
Author(s) -
Mateo I.,
Llorca J.,
Infante J.,
RodríguezRodríguez E.,
Berciano J.,
Combarros O.
Publication year - 2008
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2008.02059.x
Subject(s) - butyrylcholinesterase , allele , genotype , hyperphosphorylation , medicine , phosphorylation , alzheimer's disease , gene , disease , tau protein , endocrinology , genetics , neuroscience , aché , psychology , biology , acetylcholinesterase , biochemistry , enzyme
A loss in the regulatory mechanism that controls tau phosphorylation in normal brain is suggested to cause tau hyperphosphorylation in Alzheimer′s disease (AD) brain and the development of neurofibrillary tangles (NFT). 14‐3‐3 zeta protein and butyrylcholinesterase (BCHE) are associated with NFT in AD brain and stimulate tau phosphorylation. In a case–control study in 231 AD patients and 221 healthy controls, we examined whether the combined effects between 14‐3‐3 zeta (rs964917 and rs983583) and BCHE (K variant) polymorphisms might be responsible for susceptibility to AD. Subjects carrying both the BCHE K allele and the 14‐3‐3 zeta rs964917 G/G genotype (OR = 0.44, 95% CI = 0.20–0.95, P = 0.03), or 14‐3‐3 zeta rs983583 G/G genotype (OR = 0.46, 95% CI = 0.21–1.00, P = 0.05) had a lower risk of developing AD than subjects without these risk genotypes. Considering synergistic effects between polymorphisms in tau phosphorylation relate‐genes may help in determining the risk profile for AD.